aripiprazole / Generic mfg. - LARVOL DELTA

A case of serotonin syndrome following the reintroduction of aripiprazole after dextromethorphan overdose. (PubMed, PCN Rep) - "This case illustrates the necessity of cautious reintroduction of serotonergic or dopaminergic medications following DXM overdose. Given the potential for prolonged metabolism and interaction-especially in individuals with reduced CYP2D6 activity-clinicians should allow for adequate washout periods before restarting psychotropic agents, such as aripiprazole."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Isolated Psychosis As New Onset Cushing Syndrome (ENDO 2025) - "Further testing revealed elevated LNSC 0.42 and 0.5 mcg/dl, Dexamethasone suppression test: cortisol 16 ug/dl, dexamethasone 375 ng/dl. Patient was started on aripiprazole and evaluated by Surgery...Given possibility of temporary adrenal insufficiency due to atrophy of remaining adrenal gland, patient was started on perioperative steroids with taper to hydrocortisone 20mg qam and 10mg qpm... Psychiatric features in Cushing Syndrome can present as prodrome, during the course or even after resolution. A thorough endocrine workup can determine CS cause in the setting of adrenal and pituitary lesions."

Late-breaking abstract • CNS Disorders • Cushing’s Disease • Endocrine Disorders • Nephrology • Obesity • Psychiatry • Renal Disease • IGF1

Cabergoline Induced Psychosis in a Patient with Macroprolactinoma (ENDO 2025) - "He was started on cabergoline 1 mg twice weekly, levothyroxine 100 mcg daily, and hydrocortisone (20 mg in the morning and 10 mg in the evening)...The patient was treated with Valproate and Quetiapine...Discontinuing cabergoline typically leads to symptom resolution, though atypical antipsychotics (e.g., clozapine, aripiprazole) and mood stabilizers (e.g., lithium, valproate) have been used to manage symptoms in some cases2. This case highlights the importance of monitoring for neuropsychiatric complications in patients treated with cabergoline, even in the absence of prior psychiatric history."

Clinical • CNS Disorders • Endocrine Disorders • Hematological Disorders • Hypotension • Immunology • Mental Retardation • Nephrology • Oncology • Otorhinolaryngology • Pain • Psychiatry • Pulmonary Disease • Renal Disease • Respiratory Diseases • Vertigo • DRD2

Aripiprazole Use as a Cause for Dopamine Agonist Failure in the Treatment of Prolactinomas (ENDO 2025) - "We report the first case of aripiprazole competing with cabergoline and reducing its efficacy in the treatment of a giant prolactinoma, as evidenced by an immediate and marked rise in serum prolactin (approx. Specifically, we caution against the addition of aripiprazole to DA therapy where timely prolactinoma treatment is essential - for example, individuals with aggressive prolactinomas or those presenting with visual defects. In addition, all patients on dual aripiprazole and DA therapy for prolactinomas should be closely monitored, especially if there are risk factors for tumour aggressiveness."

CNS Disorders • Depression • Mental Retardation • Mood Disorders • Oncology • Pituitary Gland Carcinoma • Psychiatry • PRL

Unmasking a Rare Adverse Event: Olanzapine-Induced Diabetic Ketoacidosis in a Type 1 Diabetes Mellitus Patient (ENDO 2025) - "Olanzapine represents 36% of the associated antipsychotics, followed by aripiprazole at 24%, risperidone at 24%, clozapine at 12%, and quetiapine at 4%. Preventive measures, including regular risk assessment and diabetes screening before and after antipsychotic therapy, are imperative. Clinicians should closely monitor susceptible patients, considering the continuation of SGA treatment alongside proper diabetes management or screening protocols for metabolic complications."

Adverse events • Clinical • CNS Disorders • Diabetes • Epilepsy • Metabolic Disorders • Mood Disorders • Psychiatry • Rare Diseases • Type 1 Diabetes Mellitus

Late onset of striatal projection neuron hyperexcitability in Fmr1 -/y mice. (PubMed, bioRxiv) - "Chronic aripiprazole treatment, a widely prescribed therapy for FXS-related symptoms, fails to normalize SPN excitability, highlighting its limited efficacy in addressing core SPN dysfunction. Our findings reveal a late-onset hyperexcitability in DMS SPNs of Fmr1 KO mice, suggesting a progressive emergence of striatal neuron abnormalities over development. These results underscore the importance of developmental timing in FXS pathophysiology and emphasize the need for targeted interventions to address striatal circuit dysfunction."

Journal • Preclinical • Autism Spectrum Disorder • Developmental Disorders • Fragile X Syndrome • Genetic Disorders • Mental Retardation • FMR1

Long-acting injectable antipsychotics in the treatment of schizoaffective disorder: A retrospective mirror image study for hospitalizations and treatment costs. (PubMed, Asian J Psychiatr) - "After the initiation of LAI treatment, for the first-generation LAI group; there was no significant difference between the medication costs, but hospitalization costs and total treatment costs were lower and for the second-generation LAI group; the cost of medications was higher, the cost of hospitalizations was lower and the total cost of treatment was higher. Although the overall treatment cost rises due to the high prices of second-generation LAIs relative to hospitalization costs in our country, the reduction in hospitalizations associated with both groups of LAI in schizoaffective disorder is an outstanding outcome that is important for both patients and the community."

Journal • Retrospective data • CNS Disorders • Psychiatry • Schizophrenia

Influence of CYP2D6 Genotypes and Phenotypes on the Plasma Levels and Clinical Response to Aripiprazole. (PubMed, Schizophr Bull) - "CYP2D6 poor metabolism was associated with increased aripiprazole and aripiprazole plus dehydroaripiprazole concentrations-to-dose. CYP2D6 extreme phenotypes were associated with increased risk of treatment discontinuation over 1 year of treatment. This finding supports the applicability of pre-emptive CYP2D6 genotyping, which is expected to decrease aripiprazole adverse events and inefficacy that would probably lead to treatment discontinuation."

Journal • CNS Disorders

Substance Misuse To Psychosis for Stimulants (clinicaltrials.gov) - P2/3 | N=165 | Completed | Sponsor: The University of Hong Kong | Recruiting ➔ Completed | N=240 ➔ 165

Enrollment change • Trial completion • CNS Disorders • Psychiatry • Schizophrenia

Navigating the challenges of substance use and psychopathology in depression, bipolar disorder, and schizophrenia. (PubMed, Compr Psychiatry) - "Overall, most manuscripts recording SUDs concerned the following drugs: alcohol (N = 26), cannabis (N = 19), opioids (N = 10), cocaine (N = 10), and amphetamine (N = 3), while several studies described SUDs in general (N = 12)...In the case of psychotic symptoms and SUDs, aripiprazole appeared to be the most used medication in the maintenance therapy not only for its effectiveness but also for its safety profile. Alternatively, despite the side effects, clozapine showed a good efficacy in the management of symptoms and in terms of relapse prevention...With regard to the treatment of MDD/BD and SUDs, there are mixed findings regarding the best medication for symptom control; notably, different degrees of efficacy were recorded if added to psychological/behavioural interventions, or combined with specific SUD treatments, such as opioid receptor agonist/antagonist therapies or the anti-glutamatergic drugs..."

Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Schizophrenia

Reducing burst release and enhancing sustained release in SAIB-based implants: The role of polyphenol-modification. (PubMed, Eur J Med Chem) - "Here, we propose a molecular-level strategy to mitigate burst release by covalently modifying the antipsychotic drug aripiprazole (ARP) with polyphenols-specifically 4-hydroxybenzoic acid (HBA), protocatechuic acid (PCA), and gallic acid (GA)...These findings demonstrate that polyphenol modification of APIs offers a carrier-compatible, drug-centric solution for burst release regulation. Overall, this strategy significantly enhances the safety and efficacy of SAIB-based long-acting injectable systems."

Journal • CNS Disorders

Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD). (PubMed, J Affect Disord) - "Although rTMS augmentation did not reach a statistically significant difference in subjective cognitive improvement, it showed a larger effect size compared to aripiprazole augmentation. Our findings signal that rTMS augmentation may offer a well-tolerated strategy for improving cognition in TRD."

HEOR • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Body Dysmorphic Disorder and Risperidone Abuse: Exploiting Hyperprolactinemia. (PubMed, J Korean Acad Child Adolesc Psychiatry) - "Initial treatment with sertraline improved social withdrawal; however, adjunctive risperidone (0.5 mg/day) reduced tics and BDD symptoms. To the best of our knowledge, this is the first report of deliberate risperidone abuse for cosmetic hyperprolactinemia in BDD. Clinicians must monitor prolactin levels, prioritize prolactin-sparing agents (e.g., aripiprazole), and consider how adverse effects may perpetuate body image disturbances in adolescents."

Journal • CNS Disorders • Movement Disorders • Psychosomatic Disorders • Women's Health

Aripiprazole is Not Effective for Abstinence or Decreased Use in Alcohol and Stimulant Use Disorders in Patients Without Psychiatric Comorbidities: A Systematic Review. (PubMed, J Addict Med) - "We do not recommend the use of aripiprazole for alcohol use disorder (Level Of Evidence [LoE] strong, strong recommendation) for either abstinence or decreased use. Similarly, we do not recommend aripiprazole for stimulant use disorder (LoE strong, strong recommendation) in both abstinence and decreased use strategies. Our findings cannot be directly extrapolated to patients with dual diagnoses, but addiction and severe psychiatric disorders share common neurobiological pathways. While aripiprazole remains a valuable treatment option for psychiatric disorders, clinicians should closely monitor the emergence or worsening of addictive behaviors."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Mental Retardation • Psychiatry • Substance Abuse • Tobacco Addiction

Changes in Antidepressant Absorption After Metabolic Bariatric Surgery. (PubMed, Obes Surg) - "These findings suggest, in a small cohort, that chronic use of antidepressants does not require major changes in the management of patients undergoing MBS. Two distinct absorption patterns were identified for different antidepressants after surgery, highlighting the potential influence of metabolic pathways and enzymatic activity. The inverse association between D-fluoxetine CDR and BMI may be linked to changes in CYP enzyme function following MBS."

Journal

Real-World Evidence of Brexpiprazole Use and 6-Month Mortality, Hospitalization, and Emergency Department Visits Among Persons With Dementia. (PubMed, Neurology) - "Brexpiprazole use is not associated with differential mortality risk compared with aripiprazole use among PLWD. Brexpiprazole offers a treatment option which is important given the heterogeneity of effects of antipsychotics on persons. A two-stage least squares method is used to eliminate bias on estimates because of observed and unobserved differences between the 2 groups, but the small sample size is a limitation."

HEOR • Journal • Real-world evidence • Alzheimer's Disease • CNS Disorders • Dementia • Depression • Psychiatry

Subtractive proteo-genomics and model-based druggability analyses prioritized nitrate reductase-A subunit-α as potential therapeutic target against MDR pneumonia; a homology-based approach. (PubMed, BMC Microbiol) - "The current study prioritizes several druggable targets against MDR pneumonia, including the nitrate reductase-A subunit-α as a potential alternative target for developing novel anti-pneumonia therapies."

Journal • Infectious Disease • Influenza • Pneumococcal Infections • Pneumonia • Respiratory Diseases

RAKGEORREC: Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. (clinicaltrials.gov) - P4 | N=40 | Recruiting | Sponsor: Dr. Stavroula Rakitzi

New P4 trial • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia

Pharmacovigilance study of drug-induced eye movement disorder based on FDA adverse event reports from 2004 to 2024. (PubMed, Sci Rep) - "Disproportionality analysis revealed 30 drugs with significant associations with EMD, primarily within the central nervous system drug class, including antiseizure medications (vigabatrin, topiramate), antipsychotics (aripiprazole, risperidone), and antidepressants (sertraline, venlafaxine). The highest risks were observed with zonisamide (BCPNN = 3.03), vigabatrin (BCPNN = 2.82), and tiagabine (BCPNN = 2.79). Acyclovir and donepezil had the shortest onset times (median: 2 days). EMD-related adverse events were most commonly reported in middle-aged and elderly women (55.3%), and the number of cases has been steadily increasing over time. This study provides essential pharmacovigilance insights, identifying high-risk medications and demographic factors associated with drug-induced EMD, which can inform clinical practice and optimize patient care."

Adverse events • Journal • CNS Disorders • Epilepsy • Movement Disorders

Giant Prolactin-Secreting Pituitary Adenoma: A Case Report and Literature Review. (PubMed, Cureus) - "He was treated with cabergoline and levothyroxine. Due to neuropsychiatric symptoms (hallucinations, insomnia, and agitation), aripiprazole and melatonin were added...Long-term follow-up is essential to evaluate treatment response and prevent endocrine and developmental complications. Genetic testing for MEN1 or AIP mutations should be considered in young patients with aggressive pituitary adenomas."

Journal • Cardiovascular • CNS Disorders • Endocrine Cancer • Endocrine Disorders • Hypertension • Insomnia • Oncology • Pain • Pediatrics • Pituitary Gland Carcinoma • Psychiatry • Sleep Disorder • MEN1

Effect of CYP2D6 and ABCB1 polymorphisms on pharmacokinetics and efficacy of aripiprazole in pediatric tic disorders. (PubMed, BMC Pediatr) - "Pharmacokinetic parameters of ARI were correlated with CYP2D6 polymorphisms. CYP2D6 genotyping was recommended in ARI therapy. Further researches are required to elucidate the role of ABCB1 polymorphisms in ARI metabolism."

Journal • PK/PD data • Pediatrics • Tic Disorders • Tourette Syndrome • ABCB1

Management of Bipolar Disorder in Pregnancy and Postpartum: A Clinicians' Guide. (PubMed, CNS Drugs) - "These treatments include lithium, lamotrigine, other antiepileptics, quetiapine, olanzapine, aripiprazole, other antipsychotics, antidepressants, benzodiazepines, Z-drugs, and other sleep medication...In contrast, medications with a high risk for teratogenicity such as valproate and carbamazepine should be avoided in women of childbearing potential. Women with bipolar disorder are at very high risk of relapse after delivery, but this risk is more than twofold lower with adequate pharmacological prophylaxis. We advise to make a written perinatal bipolar relapse prevention plan in collaboration with the patient, family, and healthcare professionals, which includes a description of: (1) maintenance treatment during pregnancy, (2) preferred mode of delivery, (3) medication immediately after delivery and the first months postpartum for relapse prevention, (4) preferred plan for feeding (breast-feeding versus bottle-feeding), (5) strategies to assist women in ensuring adequate..."

Journal • Review • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

The treatment characteristics of oral antipsychotics in treatment of adolescents with schizophrenia in China. (PubMed, BMC Psychiatry) - "In Chinese adolescent patients, SGA is the mainstream mostly prescribed as monotherapy. Polypharmacy is observed with a steady pattern. Antipsychotics were prescribed with equal or reduced dose compared to adults DDD, and good adherence observed."

Journal • Retrospective data • CNS Disorders • Psychiatry • Schizophrenia

Determination of six psychotropic drug metabolites in human plasma by LC-MS/MS method (PubMed, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi) - "Objective: To establish a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of N-desalkylquetiapine, hydroxybupropion, N-desmethyl clozapine, N-desmethyl clomipramine, O-desmethyvenlafaxine and dehydro aripiprazole in human plasma. The linear correlation coefficients were 0.9971-0.9999, the limits of quantification of the method were 0.10-6.00 μg/L, and the inter-and intra-day precision were 4.6%-9.8% and 1.5%-8.6%, with the recoveries of the spiked standards ranged from 90.0% to 106.1%. The LC-MS/MS method for the determination of metabolites of six psychotropic drugs in human plasma is simple, rapid and sensitive, and can be used for the qualitative and quantitative determination of metabolites in plasma samples of patients suspected of psychotropic drug poisoning."

Journal

Global autism prevalence, and exploring Montessori as a practical educational solution: a systematic review. (PubMed, Front Psychiatry) - "Pharmacological agents like Risperidone and Aripiprazole can alleviate specific symptoms but do not target the core features of ASD. Montessori education, a sensory-focused, individualized, and play-based learning approach, aligns well with the individual learning needs of ASD and shows considerable potential in improving communication and social skills in children with ASD. This systematic review underscores geographic disparities and risk factors associated with autism while uniquely assessing Montessori education as a promising intervention, paving the way for further research in low-resource settings."

Journal • Review • Autism Spectrum Disorder • Genetic Disorders • Infectious Disease